Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Imago BioSciences Presented Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021; Said Bomedemstat Demonstrated Durable Clinical Improvement in Patients With ET Who Failed at Least One Standard Therapy (Usual…

By Charles Gross
Today, 8:58 PM
Imago BioSciences, Inc. ("Imago") (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia (ET).

IMGO

Read More
2 minute read

Imago BioSciences Presented Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021; Said Bomedemstat Demonstrated Encouraging and Distinct Clinical Benefit to Patients With Advanced Myelofibrosis

By Charles Gross
Today, 8:58 PM
Imago BioSciences, Inc. ("Imago") (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

IMGO